Nykode Therapeutics ASA
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
NYKD | OL
Overview
Corporate Details
- ISIN(s):
- NO0010714785
- LEI:
- 254900UKQHWYZJD22017
- Country:
- Norway
- Address:
- Gaustadalleen 21, 0349 Oslo
- Website:
- https://nykode.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies and vaccines. The company's core is its innovative, modular technology platform centered on the proprietary Vaccibody™ molecule. This platform is engineered to deliver antigens with tailored hyper-targeting to Antigen Presenting Cells, inducing rapid, robust, and long-lasting immune responses. Nykode's approach demonstrates a positive safety profile and has the potential to treat and prevent a wide range of diseases, with a significant focus on cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-24 16:40 |
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
|
English | 191.8 KB | ||
| 2025-11-24 16:40 |
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
|
English | 706 bytes | ||
| 2025-11-24 07:00 |
Earnings Release
Nykode Therapeutics - Quarterly Report Q3 2025 - Attachment: 251124 Nykode Quar…
|
English | 11.3 MB | ||
| 2025-11-24 07:00 |
Report Publication Announcement
Nykode Therapeutics - Quarterly Report Q3 2025
|
English | 3.0 KB | ||
| 2025-11-13 08:00 |
Regulatory News Service
Nykode Therapeutics – Invitation to Q3 2025 Financial Results Presentation - At…
|
Norwegian | 126.0 KB | ||
| 2025-11-13 08:00 |
Report Publication Announcement
Nykode Therapeutics – Invitation to Q3 2025 Financial Results Presentation
|
English | 3.3 KB | ||
| 2025-11-05 07:00 |
Regulatory News Service
Nykode Therapeutics to Present Data on the Strength of the Neoantigen Selection…
|
English | 221.0 KB | ||
| 2025-11-05 07:00 |
Regulatory News Service
Nykode Therapeutics to Present Data on the Strength of the Neoantigen Selection…
|
English | 6.8 KB | ||
| 2025-11-04 07:00 |
Regulatory News Service
Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. P…
|
English | 140.5 KB | ||
| 2025-11-04 07:00 |
Regulatory News Service
Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. P…
|
English | 5.3 KB | ||
| 2025-10-14 08:17 |
Major Shareholding Notification
Disclosure of Large Shareholding - Nykode Therapeutics ASA - Attachment: CGC_21…
|
English | 165.9 KB | ||
| 2025-10-14 08:17 |
Major Shareholding Notification
Disclosure of Large Shareholding - Nykode Therapeutics ASA - Attachment: SCWF_2…
|
English | 162.4 KB | ||
| 2025-10-14 08:17 |
Major Shareholding Notification
Disclosure of Large Shareholding - Nykode Therapeutics ASA
|
English | 1.0 KB | ||
| 2025-10-10 17:44 |
Director's Dealing
Nykode Therapeutics – Grant of Share Options - Attachment: Attachment Options 2…
|
English | 181.6 KB | ||
| 2025-10-10 17:44 |
Remuneration Information
Nykode Therapeutics – Grant of Share Options
|
English | 775 bytes |
Automate Your Workflow. Get a real-time feed of all Nykode Therapeutics ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nykode Therapeutics ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nykode Therapeutics ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
